Literature DB >> 32112075

Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Karen M Chisholm1,2, Mark D Fleming3.   

Abstract

OBJECTIVES: Compare the morphologic, laboratory, and clinical features of asymptomatic and symptomatic Castleman disease in the pediatric population.
METHODS: We reviewed clinical records and histopathology of patients with Castleman disease from 2 pediatric institutions.
RESULTS: Of 39 patients with pediatric Castleman disease, 37 had unicentric disease, all classified with the hyaline vascular variant of Castleman disease, 8 of which were clinically symptomatic. These 8 patients demonstrated abnormal laboratory findings, including microcytic anemia, elevated erythrocyte sedimentation rate and C-reactive protein, and hypoalbuminemia. In addition, histopathologic evaluation showed that the 8 symptomatic cases had more hyperplastic germinal centers, fewer atrophic or regressed germinal centers, fewer mantle zones containing multiple germinal centers, reduced "onion skinning" of mantle zones, and fewer "lollipop" formations compared with the asymptomatic cases.
CONCLUSIONS: This series of pediatric Castleman disease showed that lymph nodes from asymptomatic patients generally demonstrated the more classic hyaline vascular histology, whereas those with symptoms could lack or have only focal classic findings. As such, reactive lymph nodes with subtle Castleman-like features should prompt clinical correlation to ensure proper diagnosis. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Castleman disease; Lymph node; Morphology; Pediatric; Symptomatic

Mesh:

Year:  2020        PMID: 32112075      PMCID: PMC7453143          DOI: 10.1093/ajcp/aqaa011

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  37 in total

Review 1.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

Review 2.  Diagnosis and management of Castleman disease.

Authors:  Jacob D Soumerai; Aliyah R Sohani; Jeremy S Abramson
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

3.  Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.

Authors:  A R Keller; L Hochholzer; B Castleman
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

Review 4.  Pathology of Castleman Disease.

Authors:  David Wu; Megan S Lim; Elaine S Jaffe
Journal:  Hematol Oncol Clin North Am       Date:  2018-02       Impact factor: 3.722

Review 5.  Castleman disease in the pediatric neck: a literature review.

Authors:  Mindy R Rabinowitz; Jessica Levi; Katrina Conard; Udayan K Shah
Journal:  Otolaryngol Head Neck Surg       Date:  2013-03-04       Impact factor: 3.497

6.  IL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case report.

Authors:  Caroline Galeotti; Tu-Anh Tran; Stéphanie Franchi-Abella; Monique Fabre; Danièle Pariente; Isabelle Koné-Paut
Journal:  J Pediatr Hematol Oncol       Date:  2008-12       Impact factor: 1.289

7.  Renal failure in pediatric Castleman disease: Four French cases with thrombotic microangiopathy.

Authors:  Elie Cousin; Hugues Flodrops; Olivia Boyer; Julien Hogan; Mahe Ruin; Anne Couderc; Jean-Michel Goujon; Sophie Taque
Journal:  Pediatr Blood Cancer       Date:  2018-03-30       Impact factor: 3.167

Review 8.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

9.  Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.

Authors:  Katie Stone; Emily Woods; Susann M Szmania; Owen W Stephens; Tarun K Garg; Bart Barlogie; John D Shaughnessy; Brett Hall; Manjula Reddy; Antje Hoering; Emily Hansen; Frits van Rhee
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

10.  Recurrent PDGFRB mutations in unicentric Castleman disease.

Authors:  Zhaoming Li; Xuan Lan; Chaoping Li; Yanjie Zhang; Yingjun Wang; Weili Xue; Lisha Lu; Mengyuan Jin; Zhiyuan Zhou; Xinhua Wang; Ling Li; Lei Zhang; Xin Li; Xiaorui Fu; Zhenchang Sun; Jingjing Wu; Xudong Zhang; Hui Yu; Feifei Nan; Yu Chang; Jiaqin Yan; Xiaolong Wu; Guannan Wang; Dandan Zhang; Yuan Zhang; Ken H Young; Mingzhi Zhang
Journal:  Leukemia       Date:  2019-01-03       Impact factor: 11.528

View more
  2 in total

1.  Transcriptome and unique cytokine microenvironment of Castleman disease.

Authors:  Anna Wing; Jason Xu; Wenzhao Meng; Aaron M Rosenfeld; Elizabeth Y Li; Gerald Wertheim; Michele Paessler; Adam Bagg; Dale Frank; Kai Tan; David T Teachey; Megan S Lim; Eline Luning Prak; David C Fajgenbaum; Vinodh Pillai
Journal:  Mod Pathol       Date:  2021-10-22       Impact factor: 8.209

Review 2.  Pediatric Lymphoid and Histiocytic Lesions in the Head and Neck.

Authors:  A Auerbach; J J Schmieg; N S Aguilera
Journal:  Head Neck Pathol       Date:  2021-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.